All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
The Multiple Myeloma (MM) Hub are pleased to report on the current status of awaited U.S. Food & Drug Administration (FDA) approvals in MM, as well as provide a trial update from ICARIA-MM.
In October 2018, the FDA granted priority review for selinexor, a first-in-class, oral exportin 1 (XPO1) inhibitor. A meeting of the oncologic drugs advisory committee (ODAC) is scheduled for tomorrow, 26 February, 2019. The hearing will discuss the combination of selinexor and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) who have received at least three prior therapies and are refractory to at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody.1
The ODAC briefing document is available and the draft voting question for the committee centres around whether approval of selinexor should be postponed until the randomized phase III trial (BOSTON) results are available.2 The MM Hub will report on the results of this priority review once published.
The application is based on part 2 of the STORM study (KCP-330-012) which was a multicentre, open-label, single arm, phase IIb trial investigating the efficacy and safety of treatment with selinexor (80mg orally, twice weekly) and dexamethasone (20mg orally twice weekly) in 123 enrolled patients.
The FDA has been asked to approve daratumumab in combination with lenalidomide and dexamethasone (DRd) as first-line treatment for patients with NDMM, who are ineligible for stem cell transplant and high dose chemotherapy, based on the results of the MAIA phase III trial (NCT02252172).3
This request is following the results of the MAIA trial, reported during the American Society of Hematology (ASH) 60th Annual Meeting and Exposition, previously covered by the MM Hub.4 Daratumumab is an anti-CD38 monoclonal antibody, already authorized in other MM indications. The MAIA study randomized 737 patients with NDMM, non-eligible for stem cell transplant to DRd (N = 368) or Rd (N = 369). There was a 44% reduction in the risk of disease progression or death in the DRd group. A complete response or better was achieved in 48% of patients receiving DRd versus 25% in the Rd group.
The phase III ICARIA-MM trial (NCT02990338) recently met its primary endpoint of improving progression free survival (PFS) in patients with RRMM. The study investigated the use of isatuximab with pomalidomide and dexamethasone compared to pomalidomide and dexamethasone alone. The results are expected to be published during an upcoming medical meeting and the drug company responsible for the trial will use these results later in the year for regulatory submissions.5
ICARIA-MM is a multi-center, open-label, phase III trial investigating the addition of isatuximab to the two-drug regimen of pomalidomide and dexamethasone in 307 patients who were randomized. Eligible patients had received two or more prior therapies, including at least 2 cycles of lenalidomide and a PI. Isatuximab was administered intravenously (10 mg/kg) with pomalidomide and dexamethasone until disease progression or unacceptable toxicity.5
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox